These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 25496303

  • 1. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
    Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR.
    Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
    [Abstract] [Full Text] [Related]

  • 2. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
    Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR.
    Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
    [Abstract] [Full Text] [Related]

  • 3. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
    Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, Stegemann MR.
    Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
    Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR.
    Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
    Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, Follis SL, King VL, Boucher JF, Stegemann MR.
    Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
    [Abstract] [Full Text] [Related]

  • 6. Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis.
    Nuttall TJ, McEwan NA, Bensignor E, Cornegliani L, Löwenstein C, Rème CA.
    Vet Dermatol; 2012 Feb; 23(1):4-10, e1-2. PubMed ID: 21718368
    [Abstract] [Full Text] [Related]

  • 7. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Simpson AC, Schissler JR, Rosychuk RAW, Moore AR.
    Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
    [Abstract] [Full Text] [Related]

  • 8. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
    Marsella R, Ahrens K, Wilkes R, Trujillo A, Dorr M.
    Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
    [Abstract] [Full Text] [Related]

  • 9. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
    Moyaert H, Van Brussel L, Borowski S, Escalada M, Mahabir SP, Walters RR, Stegemann MR.
    Vet Dermatol; 2017 Dec; 28(6):593-e145. PubMed ID: 28906040
    [Abstract] [Full Text] [Related]

  • 10. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
    Schäfer L, Thom N.
    Vet Dermatol; 2024 Aug; 35(4):408-417. PubMed ID: 38465482
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial.
    Takahashi J, Kanda S, Imanishi I, Hisano T, Fukamachi T, Taguchi N, Momiyama S, Nishiyama S, Motegi T, Iyori K.
    Vet Dermatol; 2021 Apr; 32(2):119-e25. PubMed ID: 33185330
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
    Panteri A, Strehlau G, Helbig R, Prost C, Doucette K.
    Vet Dermatol; 2016 Feb; 27(1):22-e7. PubMed ID: 26660461
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.
    Olivry T, Lokianskiene V, Blanco A, Mestre PD, Bergvall K, Beco L.
    Vet Dermatol; 2023 Apr; 34(2):99-106. PubMed ID: 36330780
    [Abstract] [Full Text] [Related]

  • 18. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.
    Yamazaki C, Rosenkrantz W, Griffin C.
    J Small Anim Pract; 2019 Aug; 60(8):499-506. PubMed ID: 31257599
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis.
    Steffan J, Parks C, Seewald W, North American Veterinary Dermatology Cyclosporine Study Group.
    J Am Vet Med Assoc; 2005 Jun 01; 226(11):1855-63. PubMed ID: 15934253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.